Trump's 100% Section 232 Pharmaceutical Tariffs Raise Mexico Concerns Ahead of July 31 Implementation

Trade analysts and Mexican health sector representatives intensified scrutiny on April 11 of President Trump's April 2 proclamation imposing 100% Section 232 tariffs on patented pharmaceutical imports and active pharmaceutical ingredients (APIs), effective July 31, 2026. Mexico, which has a growing pharmaceutical manufacturing sector and is a significant exporter of generic and branded drugs to the U.S., is not exempt from the tariff — unlike the special carve-outs offered to the United Kingdom (10%) and some EU nations (15%). Companies that have approved onshoring plans to move manufacturing to the U.S. will face a reduced 20% rate from September 29, 2026; those entering MFN pharmaceutical pricing agreements receive a 0% rate through January 20, 2029. Mexico's USMCA exemption — which covers the 10% Section 122 general tariffs — does not appear to apply to the new Section 232 pharmaceutical proclamation. The Mexican Secretariat of Economy signaled it would seek clarification on whether USMCA dispute mechanisms could be invoked. The tariffs specifically exclude generic pharmaceuticals, biosimilars, and orphan drugs — which constitute a significant portion of Mexico's pharma export portfolio — somewhat limiting the immediate damage, but the signal remains a concern for the broader nearshoring pharmaceutical investment thesis.